Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-Label, Parallel Group Study To Investigate The Safety And Tolerability Of Multiple Dose Lersivirine (Proposed Phase 3 Formulation) For 21 Days In Healthy Subjects

NCT01230385 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01230385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01230385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-Label, Parallel Group Study To Investigate The Safety And Tolerability Of Multiple Dose Lersivirine (Proposed Phase 3 Formulation) For 21 Days In Healthy Subjects
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2010
Completion date
May 31, 2011
Enrollment
75 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers